Predictive Technology Group, Inc. Announces Letter of Intent to Acquire ReNovo Biotech, Inc.

Predictive Technology Group, Inc. (OTCPINK:PRED), through its wholly-owned subsidiary Predictive Therapeutics, Inc., announces that the Company has entered into a “Letter of Intent” to acquire ReNovo Biotech, Inc.
Bradley Robinson, CEO, Predictive Therapeutics, said:

We are very excited to announce our letter of intent to acquire ReNovo Biotech. This acquisition is one of the first steps in PRED’s strategy to expand its portfolio of products and technologies that can be used as companion treatment solutions to our molecular diagnostic tests. This will also allow us to begin clinical trials for the treatment of debilitating diseases with allogeneic and autologous stem cell products.

Eric Olson, ReNovo Biotech’s CEO stated:

We are pleased with the potential to be acquired by the publicly traded company, PRED. Utilizing PRED’s public experience and its umbrella of unique technologies gives ReNovo a multitude of opportunities that might not otherwise exist. Stem cells can be evaluated and assayed, guaranteeing those specific disease markers are NOT present prior to expanding particular cell lines used in ReNovo’s products. We believe that combining the use of molecular diagnostics with stem cell technologies will be a major breakthrough in our understanding of how stem cells are used for clinical applications.

Click here to view the full press release.